Soleno Therapeutics SLNO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Soleno Therapeutics (SLNO) Business Model and Operations Summary
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Key Insights
Soleno Therapeutics (SLNO) Core Market Data and Business Metrics
Latest Closing Price
$68.26Market Cap
$3.13 BillionPrice-Earnings Ratio
-15.58Total Outstanding Shares
45.86 Million SharesTotal Employees
92Dividend
No dividendIPO Date
November 13, 2014SIC Description
Electromedical & Electrotherapeutic ApparatusPrimary Exchange
NASDAQHeadquarters
100 Marine Parkway, Suite 400, Redwood City, CA, 94065
Historical Stock Splits
If you bought 75 shares of SLNO before October 6, 2017, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| August 26, 2022 | 1-for-15 (Reverse Split) |
| October 6, 2017 | 1-for-5 (Reverse Split) |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-69.10 Million |
| Net Cash Flow From Investing Activities, Continuing | $-225.68 Million |
| Net Cash Flow From Financing Activities, Continuing | $213.03 Million |
| Net Cash Flow From Investing Activities | $-225.68 Million |
| Net Cash Flow, Continuing | $-81.75 Million |
| Net Cash Flow | $-81.75 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Average Shares | $40.18 Million |
| Income/Loss From Continuing Operations Before Tax | $-175.85 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Net Income/Loss Attributable To Parent | $-175.85 Million |
| Nonoperating Income/Loss | $11.82 Million |
| Other Operating Expenses | $107.12 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-175.49 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-175.49 Million |
| Other Comprehensive Income/Loss | $361,000 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Intangible Assets | $6.80 Million |
| Accounts Payable | $8.88 Million |
| Wages | $4.78 Million |
| Equity | $245.11 Million |
| Liabilities And Equity | $330.97 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||